元鉴
返回中文阅读流
Nature Medicine2026-07-24

Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials

Nature Medicine, Published online: 23 July 2026; doi:10.1038/s41591-026-04534-z In a pair of pivotal phase 3, placebo-controlled, randomized clinical trials, the oral JAK1 inhibitor povorcitinib significantly reduced abscesses and inflammatory nodules in patients with moderate to severe hidradenitis suppurativa.

待翻译research literature英文原文正文翻译排队
正文翻译排队

该来源正文已进入翻译队列，中文正文生成前先展示摘要和原始出处入口。

摘要

Nature Medicine, Published online: 23 July 2026; doi:10.1038/s41591-026-04534-z In a pair of pivotal phase 3, placebo-controlled, randomized clinical trials, the oral JAK1 inhibitor povorcitinib significantly reduced abscesses and inflammatory nodules in patients with moderate to severe hidradenitis suppurativa.

Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials

Nature Medicine, Published online: 23 July 2026; doi:10.1038/s41591-026-04534-z In a pair of pivotal phase 3, placebo-controlled, randomized clinical trials, the oral JAK1 inhibitor povorcitinib significantly reduced abscesses and inflammatory nodules in patients with moderate to severe hidradenitis suppurativa.